Anti-TNF alpha in the treatment of psoriatic arthritis;Anti-TNF alpha dans le traitement du rhumatisme psoriasique

Presse Medicale

Volumn 35, Issue 4 II, 2006, Pages 647-655

  Claudepierre, Pascal ^a   Wendling, Daniel ^b   Cohen, Jean David ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; INFECTION CONTROL; PSORIATIC ARTHRITIS; PSYCHOLOGICAL ASPECT; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT INDICATION; ALGORITHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; FORECASTING; HOSPITALIZATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; FORECASTING; HUMANS; IMMUNOGLOBULIN G; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646948922     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74658-9     Document Type: Article

References (28)

1. Saraux A, Guillemin F, Guggenbuhl P, Roux CH, Fardellone P, Le-Bihan E et al. Prevalence of spondylarthropathies in France - 2001. Ann Rheum Dis. 2005; [Epub ahead of print].
2. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3: 55-78.
3. Goupille P. Which second-line treatments are optimal in psoriatic arthritis? Joint Bone Spine. 2002; 69: 244-8.
4. Wendling D, Claudepierre P, Lohse A, Toussirot E, Breban. Utilisation thérapeutigue des agents anti-TNF-α au cours des spondylarthropathies. Presse Med. 2003; 32: 1517-24.
5. Costello P, Bresnihan B, O'Farrelly C, FitzGerald O. Predominant of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999; 26: 1117-24.
6. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukine-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol. 1999; 113: 752-9.
7. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998; 25: 1544-52.
8. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumor necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994; 96: 146-51.
9. Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS. Upregulation of cytokine receptors sTNF-R55, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol. 1998; 25: 105-10.
10. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy. Histological findings in eight patients from an opel-label pilot study. Arthritis Rheum. 2001; 44: 186-95.
11. Cañete JD, Pablos JL, Sanmartí R, Mallofré C, Marsal S, Maymó J et al. Antiangiogenic effects of anti-Tumor Necrosis Factor α therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 2004; 50: 1636-41.
12. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C et al. A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997; 109: 562-5.
13. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int. 2002; 22: 227-32.
14. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Res. 2002; 47: 506-12.
15. Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Care Res. 2003; 49: 541-5.
16. Provenzano G, Termini A, Le Moli C, Rinaldi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis. 2003; 62: 680-1.
17. Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis. 2004; 63: 156-61.
18. Antoni C, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester G, Schneider U et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005; 52: 1227-36.
19. Antoni C, Kavanaugh A, Gladman D, Wassenberg S, Zhou B, Beutler A et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Arthritis Rheum. 2004; 50: S450.
20. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Feb 24; [Epub ahead of print]
21. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol. 2000; 18: 732-4.
22. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356: 385-90.
23. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen S, Ory P et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy and effect on disease progression. Arthritis Rheum. 2004; 50: 2264-72.
24. Ritchlin C, Anandarajaha A, Totterman S, Shao T, Kemshatti S, Badger W et al. Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis. Ann Rheum Dis. 2004; 63 (suppl 1): 403.
25. Mease PJ, Gladman D, Ritchlin C, Ruderman E, Steinfeld D, Choy E et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum. 2004; 50: 4097.
26. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P et al. Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004; 50: 1939-50.
27. Kyle S, Chandler D, Griffiths CEM, Helliwell P, Lewis J, McInnes I et al on behalf of the Bristish Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG). Guidelines for anti-TNF-α therapy in psoriatic arthritis. Rheumatology. 2005; 44: 390-7.
28. Mease PJ, Gladman DD, Krueger GG. Group for Research and Assessment on Psoriasis and Psoriatic Arthritis (GRAPPA). Ann Rheum Dis. 2005; 64: ii1-ii2.